key: cord-1042659-vc3lhm0f
authors: Di Lernia, Vito
title: Biologics for psoriasis during COVID-19 outbreak
date: 2020-04-10
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.04.004
sha: 5c5ec1287cac013ef028aec2652eb8508598f5bb
doc_id: 1042659
cord_uid: vc3lhm0f

nan

for psoriasis be interrupted in the era of COVID-19?" 1 . We share the concern that has been expressed about the possible impact of biologic therapies on the patient's susceptibility to COVID-19 infection. In addition to the infectious complications for biologic therapies reported during pivotal trials for psoriasis, we would like to draw attention to other aspects that might guide the decision whether to continue biologic therapy during the COVID-19 pandemic. 

Should biologics for psoriasis be interrupted in the era of COVID-19?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

Should patients stop their biologic treatment during the COVID-19 pandemic

MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile